Free Trial

Blair William & Co. IL Has $289,000 Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Moderna logo with Medical background

Blair William & Co. IL lessened its position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 60.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,200 shares of the company's stock after selling 15,740 shares during the quarter. Blair William & Co. IL's holdings in Moderna were worth $289,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Voloridge Investment Management LLC lifted its stake in Moderna by 335.6% in the fourth quarter. Voloridge Investment Management LLC now owns 2,590,831 shares of the company's stock valued at $107,727,000 after buying an additional 1,996,003 shares during the period. Deutsche Bank AG lifted its stake in Moderna by 54.7% in the fourth quarter. Deutsche Bank AG now owns 1,894,075 shares of the company's stock valued at $78,756,000 after buying an additional 669,614 shares during the period. TB Alternative Assets Ltd. acquired a new position in Moderna in the first quarter valued at about $18,495,000. Federated Hermes Inc. lifted its stake in Moderna by 152,061.1% in the first quarter. Federated Hermes Inc. now owns 617,774 shares of the company's stock valued at $17,514,000 after buying an additional 617,368 shares during the period. Finally, Bridgewater Associates LP acquired a new position in Moderna in the fourth quarter valued at about $25,188,000. Institutional investors and hedge funds own 75.33% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Evercore ISI set a $32.00 target price on Moderna in a research note on Friday, August 1st. William Blair restated a "market perform" rating on shares of Moderna in a report on Monday, June 2nd. Wells Fargo & Company restated an "equal weight" rating on shares of Moderna in a report on Sunday, July 13th. Royal Bank Of Canada lowered their price target on Moderna from $32.00 to $28.00 and set a "sector perform" rating for the company in a report on Friday, May 2nd. Finally, Cowen began coverage on Moderna in a report on Sunday, July 13th. They issued a "hold" rating for the company. Four equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Moderna currently has an average rating of "Hold" and a consensus price target of $43.59.

Get Our Latest Analysis on Moderna

Moderna Stock Performance

Shares of NASDAQ MRNA opened at $25.66 on Wednesday. The stock has a 50 day moving average price of $29.19 and a 200 day moving average price of $29.75. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $91.99. The stock has a market capitalization of $9.98 billion, a PE ratio of -3.41 and a beta of 1.83.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The company reported ($2.13) EPS for the quarter, beating the consensus estimate of ($2.99) by $0.86. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%. The firm had revenue of $142.00 million during the quarter, compared to analysts' expectations of $116.26 million. During the same period in the prior year, the firm posted ($3.33) earnings per share. The business's quarterly revenue was down 41.1% compared to the same quarter last year. As a group, research analysts forecast that Moderna, Inc. will post -9.61 EPS for the current year.

Moderna Company Profile

(Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

See Also

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA - Free Report).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Moderna Right Now?

Before you consider Moderna, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.

While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Overlooked Stocks Riding the AI Data Center Boom
3 Growth Stock Winners to Watch And 3 to Avoid
3 Growth Stocks That Could Pop Before Summer Ends

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines